🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,911 results for “Pharma” Clear

  1. 608 Q2W

    Sunshine Biopharma

    Psoriasis

    phase 3 small molecule completed

    1 trial

  2. 608 dose

    Sunshine Biopharma

    Ankylosing Spondylitis

    phase 3 small molecule active

    1 trial

  3. 610

    Sunshine Biopharma

    Asthma

    phase 3 small molecule active

    2 trials

  4. 611

    Sunshine Biopharma

    Dermatitis, Atopic

    phase 3 small molecule active

    3 trials

  5. 611

    Sunshine Biopharma

    Pulmonary Disease, Chronic Obstructive (COPD)

    phase 3 small molecule active

    1 trial

  6. 611

    Sunshine Biopharma

    Sinusitis

    phase 3 small molecule active

    2 trials

  7. 68Ga-PSMA-11

    China SXT Pharmaceuticals

    Biochemical Recurrence of Malignant Neoplasm of Prostate

    phase 3 small molecule active

    1 trial

  8. 750 mg Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 3 small molecule completed

    1 trial

  9. 9vHPV Vaccine

    Takeda Pharmaceuticals International AG

    Dengue Fever

    phase 3 mab completed

    1 trial

  10. A 52-Week, Open-Label Extension Study of ACP-204 in Adults with Alzheimer's Disease Psychosis

    Pharma Mar S.A.

    Alzheimer's Disease Psychosis

    phase 3 other active

    1 trial

  11. A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

    Pharma Mar S.A.

    Lewy body Dementia psychosis (LBDP)

    phase 3 other active

    1 trial

  12. A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)

    Roche Registration Limited

    Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

    phase 3 other active

    1 trial

  13. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis

    Roche Registration Limited

    NMDAR or LGI1 mediated autoimmune Encephalitis

    phase 3 other active

    1 trial

  14. A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

    Amgen Technology (Ireland) UC

    Early-stage Non-squamous Non-small Cell Lung Cancer

    phase 3 other active

    1 trial

  15. A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy

    Roche Registration Limited

    Spinal Muscular Atrophy (SMA)

    phase 3 other active

    1 trial

  16. A clinical study is aimed at comparing the effectiveness of two types of cell therapy in treating anal fistulas associated with Crohn's disease.

    COLLEGIUM PHARMACEUTICAL, INC

    Anal or recto-cutaneous or recto-vaginal Crohn-related fistula

    phase 3 other active

    1 trial

  17. A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)

    Takeda Pharmaceuticals International AG

    Dravet and Lennox-Gastaut Syndromes

    phase 3 other active

    1 trial

  18. A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

    Sanofi Pharma Bristol-Myers Squibb

    Immune system diseases

    phase 3 other active

    1 trial

  19. A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-small cell lung cancer

    Mabxience Research SL

    advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  20. ABIRATERONE ACETATE, ABIRATERONE ACETATE, ENZALUTAMIDE, ABIRATERONE ACETATE, Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation, ENZALUTAMIDE, ENZALUTAMIDE

    Novartis Ophthalmics Europe

    PSMA-positive metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  21. ABIRATERONE ACETATE, DAROLUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, APALUTAMIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion, ENZALUTAMIDE

    Cancer Prevention Pharma (Ireland) Limited

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  22. ABIRATERONE, 177Lu-PNT2002, GALLIUM (68GA) GOZETOTIDE , ENZALUTAMIDE

    Pharma Mar S.A.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  23. ABO-102, ABO-102, ABO-102

    Pharma Mar S.A.

    Mucopolysaccharidosis type IIIA

    phase 3 small molecule active

    1 trial

  24. ACARD 300 mg, 300 mg, tabletki, Microcrystalline cellulose, Native corn starch, Citric acid anhydrous (E330)

    COLLEGIUM PHARMACEUTICAL, INC

    aspirin-exacerbated respiratory disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources